GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veritas In Silico Inc (TSE:130A) » Definitions » Total Long-Term Liabilities

Veritas In Silico (TSE:130A) Total Long-Term Liabilities : 円0.0 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Veritas In Silico Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Veritas In Silico's Total Long-Term Liabilities for the quarter that ended in Dec. 2024 was 円0.0 Mil.


Veritas In Silico Total Long-Term Liabilities Historical Data

The historical data trend for Veritas In Silico's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veritas In Silico Total Long-Term Liabilities Chart

Veritas In Silico Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Total Long-Term Liabilities
- - - -

Veritas In Silico Quarterly Data
Dec21 Dec22 Sep23 Dec23 Mar24 Jun24 Dec24
Total Long-Term Liabilities Get a 7-Day Free Trial - - - - -

Veritas In Silico Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.


Veritas In Silico Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Veritas In Silico's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Veritas In Silico Business Description

Traded in Other Exchanges
N/A
Address
1-11-1, Nishigotanda, Shinagawa-ku, Tokyo, JPN, 141-0031
Veritas In Silico Inc is engaged in discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. It has ibVIS platform that combines informatics (i) and experimental biology at Veritas In Silico (VIS) that will bring to fruition mRNA-targeted drugs.

Veritas In Silico Headlines

No Headlines